Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

AKTX - Akari Therapeutics, Plc Latest News | Finranks

Home

AKTX

A

Akari Therapeutics, Plc (AKTX)

NCM – Real Time Price. Currency in USD

0.13

-0.01 (-7.40%)

At close: Mar 27, 2026, 4:00 PM EDT

0.13

+0.00 (0.48%)

After-hours: Mar 27, 2026, 4:15 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026

Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026

TAMPA, Fla. and LONDON, March 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, today announced its abstract has been accepted for poster presentation at the American Association for Cancer Research Annual Meeting 2026, being held April 17–22, 2026.

Akari Therapeutics Announces ADS Ratio Change

Akari Therapeutics Announces ADS Ratio Change

TAMPA, Fla. and LONDON, March 17, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, today announced that the Company will change the ratio of its American Depositary Shares (ADSs) to ordinary shares from one ADS representing two thousand (2,000) ordinary shares to a new ratio of one ADS representing eighty thousand (80,000) ordinary shares. The ratio change is expected to be effective on March 31, 2026.

Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala

Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala

Highlights strategic progress achieved under Abizer Gaslightwala's leadership, including advancement of AKTX-101 and expansion of Akari's ADC pipeline

Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board

Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board

TAMPA, Fla. and LONDON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today announced the appointment of Prafulla Gokhale, Ph.D.

Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference

Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference

TAMPA, Fla. and LONDON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today announced that Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics, will present at the 2026 Biocom Global Partnering & Investor Conference, being held February 24–26, 2026, at The Lodge at Torrey Pines in San Diego, CA.

Akari Therapeutics, Plc (AKTX) Discusses New Patent Filing and Expansion of ADC Pipeline for Solid Tumors Transcript

Akari Therapeutics, Plc (AKTX) Discusses New Patent Filing and Expansion of ADC Pipeline for Solid Tumors Transcript

Akari Therapeutics, Plc (AKTX) Discusses New Patent Filing and Expansion of ADC Pipeline for Solid Tumors Transcript

Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company's Expanded ADC Pipeline

Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company's Expanded ADC Pipeline

CEO Abizer Gaslightwala discusses the Company's recent announcement around its ADC pipeline expansion and IP strategy

Videos

No Data

There is no data to display

Press releases

Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026

Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026

TAMPA, Fla. and LONDON, March 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, today announced its abstract has been accepted for poster presentation at the American Association for Cancer Research Annual Meeting 2026, being held April 17–22, 2026.

Akari Therapeutics Announces ADS Ratio Change

Akari Therapeutics Announces ADS Ratio Change

TAMPA, Fla. and LONDON, March 17, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, today announced that the Company will change the ratio of its American Depositary Shares (ADSs) to ordinary shares from one ADS representing two thousand (2,000) ordinary shares to a new ratio of one ADS representing eighty thousand (80,000) ordinary shares. The ratio change is expected to be effective on March 31, 2026.

Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala

Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala

Highlights strategic progress achieved under Abizer Gaslightwala's leadership, including advancement of AKTX-101 and expansion of Akari's ADC pipeline

Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board

Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board

TAMPA, Fla. and LONDON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today announced the appointment of Prafulla Gokhale, Ph.D.